Rx Reimbursement Model Must Change For Pharma To Flourish, Castellani Says
Executive Summary
The pharmaceutical industry must work to change two "insidious" reimbursement paradigms if it hopes to be able to continue to develop additional medications, PhRMA CEO John Castellani said in his first major policy address.
You may also be interested in...
Can Jersey City Be A Cure For What Ails Pharma?
One of the highlights of the Pharmaceutical Research & Manufacturers of America's annual meeting in Jersey City, N.J., was a fill-in-the-blank exercise.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.